Your browser doesn't support javascript.
loading
Glycemic control after switching to faster aspart in adults with type 1 diabetes.
Fadini, G P; Boscari, F; Falaguasta, D; Ferretto, S; Maran, A; Avogaro, A; Bruttomesso, D.
Afiliación
  • Fadini GP; Department of Medicine - DIMED, Division of Metabolic Disease, University of Padova, Via Giustiniani 2, 35128, Padua, Italy. gianpaolo.fadini@unipd.it.
  • Boscari F; Division of Metabolic Disease, University Hospital of Padova, Padua, Italy. gianpaolo.fadini@unipd.it.
  • Falaguasta D; Department of Medicine - DIMED, Division of Metabolic Disease, University of Padova, Via Giustiniani 2, 35128, Padua, Italy.
  • Ferretto S; Division of Metabolic Disease, University Hospital of Padova, Padua, Italy.
  • Maran A; Division of Metabolic Disease, University Hospital of Padova, Padua, Italy.
  • Avogaro A; Division of Metabolic Disease, University Hospital of Padova, Padua, Italy.
  • Bruttomesso D; Department of Medicine - DIMED, Division of Metabolic Disease, University of Padova, Via Giustiniani 2, 35128, Padua, Italy.
J Endocrinol Invest ; 45(6): 1181-1188, 2022 Jun.
Article en En | MEDLINE | ID: mdl-35103951
ABSTRACT

AIMS:

Post-prandial hyperglycemia remains an unmet need in the management of type 1 diabetes (T1D). In randomized trials, faster insulin aspart (FIA) showed modest but significant reductions of glycemic spikes after meals. Whether such benefit is evident in routine clinical practice is unclear.

METHODS:

We analyzed data of patients with T1D at the time they switched from a prior bolus insulin to FIA and at the first available follow-up. The primary endpoint was the change in the time spent in hyperglycemia > 250 mg/dl during daytime from flash glucose monitoring (FGM). Secondary outcomes included the change in HbA1c, body weight, insulin dose and other FGM metrics.

RESULTS:

We included 117 patients with T1D on multiple daily injections who switched to FIA, 57 of whom had data from FGM. Patients were 41-year-old, 51.3% men, with 19.3 years diabetes duration and a baseline HbA1c of 7.7% (60 mmol/mol). Mean observation time was 4.3 months. After switching to FIA, HbA1c declined by 0.1% (1 mmol/mol) only in patients with baseline HbA1c > 7.0% (53 mmol/mol). Time spent in hyperglycemia > 250 mg/dl during daytime was significantly reduced from 14.8 to 11.9% (p = 0.006). Time in range improved from 48.3 to 51.0% (p = 0.028). Results were consistent across various patient characteristics.

CONCLUSIONS:

Under routine care, patients with T1D who switched to FIA experienced a reduction in the time spent in hyperglycemia > 250 mg/dl during daytime and an increase in time in range. These improvements may be due to better control of post-prandial hyperglycemia, as observed in trials.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 1 / Hiperglucemia Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male Idioma: En Revista: J Endocrinol Invest Año: 2022 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 1 / Hiperglucemia Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male Idioma: En Revista: J Endocrinol Invest Año: 2022 Tipo del documento: Article País de afiliación: Italia